Akorn, CSL sign distribution deal

BUFFALO GROVE -- Akorn Inc., a specialty pharmaceutical company, and CSL Biotherapies Inc., a subsidiary of CSL Ltd., have entered into an distribution agreement for Afluria, a seasonal influenza vaccine. Akorn will market and distribute two presentations of Afluria, which has pre-filled syringes without latex or thimerosal, and preserved multi-dose vials. Akorn will begin sales for the 2008 flu season.